Literature DB >> 28952039

Unusually high levels of serum p53 antibody in recurrent gastric cancer.

Masaki Kunizaki1,2, Keiko Hamasaki3, Kouki Wakata3, Shigekazu Hidaka3, Takeshi Nagayasu3, Yukie Kinoshita4.   

Abstract

Serum tumor markers in patients with cancer assist with establishing diagnosis, estimating prognosis, monitoring treatment, and detecting tumor recurrence. Changes in the p53 tumor suppressor gene are the most common genetic abnormalities in many different human malignancies. Several studies have demonstrated that serum p53 antibodies (S-p53Ab) comprise an early marker of malignant disease, a marker for treatment effects and a prognostic factor for patients with several types of tumors. We recently reported that S-p53Ab is useful for patients with gastric cancer. We describe a rare situation in which unusually high serum p53 antibodies helped to detect recurrent gastric cancer in the small intestine after gastrectomy. Further studies are required to gain a more precise understanding of the clinical impact of S-p53Ab titer monitoring in gastric cancer.

Entities:  

Keywords:  Gastric cancer; Recurrence; S-p53Ab; Tumor marker

Mesh:

Substances:

Year:  2017        PMID: 28952039     DOI: 10.1007/s12328-017-0780-x

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  11 in total

1.  Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.

Authors:  Hiroki Ochiai; Takashi Ohishi; Koji Osumi; Jo Tokuyama; Hidejirou Urakami; Shikou Seki; Atsushi Shimada; Akira Matsui; Yoh Isobe; Yuya Murata; Takashi Endo; Yoshiyuki Ishii; Hirotoshi Hasegawa; Sumio Matsumoto; Yuko Kitagawa
Journal:  Surg Today       Date:  2011-11-11       Impact factor: 2.549

2.  Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer.

Authors:  Takayuki Suzuki; Hideaki Shimada; Mitsunori Ushigome; Junichi Koike; Kimihiko Funahashi; Tetsuo Nemoto; Hironori Kaneko
Journal:  Clin J Gastroenterol       Date:  2016-02-26

3.  Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.

Authors:  Shinichi Yachida; Catherine M White; Yoshiki Naito; Yi Zhong; Jacqueline A Brosnan; Anne M Macgregor-Das; Richard A Morgan; Tyler Saunders; Daniel A Laheru; Joseph M Herman; Ralph H Hruban; Alison P Klein; Siân Jones; Victor Velculescu; Christopher L Wolfgang; Christine A Iacobuzio-Donahue
Journal:  Clin Cancer Res       Date:  2012-09-18       Impact factor: 12.531

4.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

5.  Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.

Authors:  Masaki Kunizaki; Akiko Fukuda; Kouki Wakata; Tetsuro Tominaga; Takashi Nonaka; Takuro Miyazaki; Keitaro Matsumoto; Yorihisa Sumida; Shigekazu Hidaka; Toru Yasutake; Terumitsu Sawai; Ryuji Hamamoto; Atsushi Nanashima; Takeshi Nagayasu
Journal:  Anticancer Res       Date:  2017-04       Impact factor: 2.480

6.  Negative conversion of high serum p53 antibody titers in a patient with gastric cancer at 31 months after surgery.

Authors:  Kenji Murayama; Tatsuki Nanami; Takashi Suzuki; Yoko Oshima; Satoshi Yajima; Tetsuo Nemoto; Hideaki Shimada
Journal:  Clin J Gastroenterol       Date:  2017-05-24

7.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers.

Authors:  Sohrab P Shah; Andrew Roth; Rodrigo Goya; Arusha Oloumi; Gavin Ha; Yongjun Zhao; Gulisa Turashvili; Jiarui Ding; Kane Tse; Gholamreza Haffari; Ali Bashashati; Leah M Prentice; Jaswinder Khattra; Angela Burleigh; Damian Yap; Virginie Bernard; Andrew McPherson; Karey Shumansky; Anamaria Crisan; Ryan Giuliany; Alireza Heravi-Moussavi; Jamie Rosner; Daniel Lai; Inanc Birol; Richard Varhol; Angela Tam; Noreen Dhalla; Thomas Zeng; Kevin Ma; Simon K Chan; Malachi Griffith; Annie Moradian; S-W Grace Cheng; Gregg B Morin; Peter Watson; Karen Gelmon; Stephen Chia; Suet-Feung Chin; Christina Curtis; Oscar M Rueda; Paul D Pharoah; Sambasivarao Damaraju; John Mackey; Kelly Hoon; Timothy Harkins; Vasisht Tadigotla; Mahvash Sigaroudinia; Philippe Gascard; Thea Tlsty; Joseph F Costello; Irmtraud M Meyer; Connie J Eaves; Wyeth W Wasserman; Steven Jones; David Huntsman; Martin Hirst; Carlos Caldas; Marco A Marra; Samuel Aparicio
Journal:  Nature       Date:  2012-04-04       Impact factor: 49.962

8.  Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma.

Authors:  Hideaki Shimada; Tooru Shiratori; Akihiko Takeda; Kazuyuki Matsushita; Shinichi Okazumi; Yasunori Akutsu; Hisahiro Matsubara; Fumio Nomura; Takenori Ochiai
Journal:  World J Surg       Date:  2009-02       Impact factor: 3.352

9.  Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.

Authors:  Hideaki Shimada; Takenori Ochiai; Fumio Nomura
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

10.  Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade.

Authors:  C W Wu; Y Y Lin; G D Chen; C W Chi; D P Carbone; J Y Chen
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.